[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
1. Jang SY, Kong MH, Song KY, Frazee JG: Intracranial Metastases of Cervical Intramedullary Low-Grade Astrocytoma without Malignant Transformation in Adult. J Korean Neurosurg Soc; 2009 Jun;45(6):381-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial Metastases of Cervical Intramedullary Low-Grade Astrocytoma without Malignant Transformation in Adult.
  • The first case of intracranial metastases of a cervical intramedullary low-grade astrocytoma without malignant transformation in adult is presented in this report.
  • Seven years ago, a 45 year-old male patient underwent biopsy to confirm pathologic characteristics and received craniocervical radiation and chemotherapy for a grade II astrocytoma in the cervical spinal cord.
  • The tumor at the cervical and brain lesions was classified as an astrocytoma (WHO grade II).
  • When a patient with low-grade astrocytoma in the spinal cord has new cranial symptoms after surgery, radiaton, and chemotherapy, the possibility of its metastasis should be suspected because it can spread to the intracranial cavity even without malignant transformation as shown in this case.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2000 Dec;50(3):239-43 [11263503.001]
  • [Cites] J Clin Neurosci. 2001 Jul;8(4):374-7 [11437586.001]
  • [Cites] Spinal Cord. 2006 Dec;44(12):740-5 [16670687.001]
  • [Cites] Childs Nerv Syst. 2005 Jun;21(6):477-81 [15378329.001]
  • [Cites] Neurosurgery. 2005;56(1):191 [15617606.001]
  • [Cites] Med Pediatr Oncol. 1997 Dec;29(6):560-2 [9324344.001]
  • [Cites] Neurosurgery. 1997 Jan;40(1):141-51 [8971836.001]
  • [Cites] J Neurooncol. 1995;25(3):245-50 [8592175.001]
  • [Cites] J Neurosurg. 1995 Sep;83(3):480-5 [7666226.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):590-5 [7674006.001]
  • [Cites] J Neurosurg. 1995 Jul;83(1):67-71 [7782852.001]
  • [Cites] J Neurooncol. 1994;18(1):49-52 [8057134.001]
  • [Cites] Neurol Med Chir (Tokyo). 1992 May;32(5):281-4 [1378944.001]
  • [Cites] J Neurosurg. 1992 Sep;77(3):355-9 [1506881.001]
  • [Cites] J Neurosurg. 1988 Aug;69(2):295-300 [3392575.001]
  • [Cites] Cancer. 1982 Aug 15;50(4):732-5 [7093908.001]
  • [Cites] Br J Surg. 1975 Feb;62(2):92-5 [1115920.001]
  • [Cites] Pediatr Blood Cancer. 2004 Nov;43(6):629-32 [15390309.001]
  • [Cites] Childs Nerv Syst. 2004 Feb;20(2):114-8 [14762681.001]
  • [Cites] Cancer. 2003 Aug 1;98(3):554-61 [12879473.001]
  • [Cites] Curr Opin Neurol. 2001 Dec;14(6):679-82 [11723373.001]
  • [Cites] Surg Neurol. 2001 Jul;56(1):39-41 [11546571.001]
  • [Cites] J Neurosurg. 2006 Dec;105(6 Suppl):508-14 [17184088.001]
  • (PMID = 19609424.001).
  • [ISSN] 2005-3711
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2711238
  • [Keywords] NOTNLM ; Astrocytoma / Cranial metastases / Intramedullary / Spinal cord tumor
  •  go-up   go-down


2. Badhe PB, Chauhan PP, Mehta NK: Brainstem gliomas--a clinicopathological study of 45 cases with p53 immunohistochemistry. Indian J Cancer; 2004 Oct-Dec;41(4):170-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The WHO brain tumor classification and Stroink's CT classification were applied.
  • Diffuse astrocytomas were seen in 40 cases (5% were Grade I, 47.5%Grade II, 32.5% Grade III and 15% Grade IV) and pilocytic astrocytomas in 5 cases.
  • Grade IV patients had 2- 3 mitoses /10 high power fields and had a poorer survival rate.
  • Grade II astrocytomas were treated with excision and radiotherapy, while grade III and IV tumors were treated with radiotherapy and chemotherapy (CCNU).
  • The outcome was better in patients who were treated surgically. p53 is a frequently mutated gene in brain stem astrocytomas.
  • It was found in 50 % of glioblastoma multiforme, 28.57% of grade III astrocytoma and 12.5% of grade II astrocytoma, while grade 1 astrocytomas failed to express p53 protein. p53 positivity was more in high grade lesions, decreasing significantly in lower grade lesions.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Brain Stem Neoplasms / metabolism. Glioma / metabolism. Tumor Suppressor Protein p53 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15659871.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


3. Maria BL, Gupta N, Gilg AG, Abdel-Wahab M, Leonard AP, Slomiany M, Wheeler WG, Tolliver LB, Babcock MA, Lucas JT Jr, Toole BP: Targeting hyaluronan interactions in spinal cord astrocytomas and diffuse pontine gliomas. J Child Neurol; 2008 Oct;23(10):1214-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting hyaluronan interactions in spinal cord astrocytomas and diffuse pontine gliomas.
  • Although significant advances have been made in treating malignant pediatric central nervous system tumors such as medulloblastoma, no effective therapy exists for diffuse pontine glioma or intramedullary spinal astrocytoma.
  • Biology of these 2 tumors is poorly understood, in part because diffuse pontine gliomas are not treated surgically, and tumor specimens from intramedullary spinal astrocytomas are rare and minuscule.
  • At the 2007 Neurobiology of Disease in Children Symposium, we presented evidence that malignant glioma behaviors, including antiapoptosis, invasiveness, and treatment resistance, are enhanced by hyaluronan, an extracellular glycosaminoglycan.
  • We review the clinical course of pediatric intramedullary spinal astrocytoma and diffuse pontine glioma, and show expression of membrane proteins that interact with hyaluronan: CD44, extracellular matrix metalloproteinase inducer, and breast cancer resistance protein (BCRP/ABCG2).
  • These findings suggest that hyaluronan antagonism has potential therapeutic value in malignant central nervous system tumors.
  • [MeSH-major] Astrocytoma / metabolism. Brain Stem Neoplasms / metabolism. Glioma / metabolism. Hyaluronic Acid / metabolism. Spinal Cord Neoplasms / metabolism
  • [MeSH-minor] ATP Binding Cassette Transporter, Sub-Family G, Member 2. ATP-Binding Cassette Transporters / genetics. ATP-Binding Cassette Transporters / metabolism. Animals. Basigin / genetics. Basigin / metabolism. Child. Disease Models, Animal. Drug Resistance, Neoplasm / genetics. Humans. Hyaluronan Receptors / genetics. Hyaluronan Receptors / metabolism. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Rats

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1998 Feb;88(2):215-20 [9452226.001]
  • [Cites] Clin Cancer Res. 2008 Mar 15;14(6):1804-13 [18347183.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):172-87 [16014887.001]
  • [Cites] Oncogene. 2005 Nov 14;24(50):7482-92 [16288295.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1060-71 [16373081.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Apr 20;355(4):855-9 [17307142.001]
  • [Cites] Br J Cancer. 1999 Nov;81(5):835-40 [10555754.001]
  • [Cites] Int J Cancer. 2000 Oct 1;88(1):21-7 [10962435.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):1921-8 [11395366.001]
  • [Cites] J Surg Oncol. 2002 Jan;79(1):30-5; discussion 35-6 [11754374.001]
  • [Cites] J Neurooncol. 2002 Nov;60(2):127-34 [12635659.001]
  • [Cites] Am J Pathol. 2003 May;162(5):1403-9 [12707023.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1229-32 [14983875.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jun;36(6):1046-69 [15094120.001]
  • [Cites] Nat Rev Cancer. 2004 Jul;4(7):528-39 [15229478.001]
  • [Cites] Eur J Cancer. 1993;29A(7):1012-7 [7684596.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):434-9 [7812975.001]
  • [Cites] Int J Cancer. 1996 Apr 10;66(2):255-60 [8603821.001]
  • [Cites] J Pathol. 1997 Apr;181(4):434-8 [9196442.001]
  • [Cites] Glia. 1997 Jul;20(3):193-202 [9215728.001]
  • [Cites] Regen Med. 2006 Jul;1(4):437-45 [17465836.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):275-84 [15803154.001]
  • (PMID = 18952588.001).
  • [ISSN] 1708-8283
  • [Journal-full-title] Journal of child neurology
  • [ISO-abbreviation] J. Child Neurol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R13 NS040925; United States / NCI NIH HHS / CA / R01 CA073839; United States / NINDS NIH HHS / NS / 5R13NS040925-09; United States / NCRR NIH HHS / RR / C06RR015455; United States / NCI NIH HHS / CA / R01 CA082867; United States / NCI NIH HHS / CA / CA073839; United States / NCRR NIH HHS / RR / C06 RR015455; United States / NCI NIH HHS / CA / CA082867
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / BSG protein, human; 0 / Hyaluronan Receptors; 0 / Neoplasm Proteins; 136894-56-9 / Basigin; 9004-61-9 / Hyaluronic Acid
  • [Number-of-references] 23
  • [Other-IDs] NLM/ NIHMS463105; NLM/ PMC3641563
  •  go-up   go-down


Advertisement
4. Novillo López ME, Gómez-Ibáñez A, Rosenfeld M, Dalmau J: [Gliomatosis cerebri: review of 22 patients]. Neurologia; 2010 Apr;25(3):168-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Gliomatosis cerebral: estudio de 22 pacientes.
  • INTRODUCTION: gliomatosis cerebri is a diffuse astrocytic neoplasm that involves more than two lobes of the brain.
  • Treatment is not well defined and the prognosis is considered poor.
  • The most frequent pathological findings were grade III astrocytoma (36.4%), grade II astrocytoma (22.7%), and grade IV astrocytoma (18.3%).
  • Seventeen patients received treatment with chemotherapy, radiotherapy or both, and 12 patients (70.6%) had a clinical or radiological response.
  • The median follow-up was 13 months, median progression free survival 6 months, and median survival 9,5 months (15 months if the patients received treatment).
  • Treatment often results in clinical responses.
  • In this study de median survival of patients who received treatment was similar to that reported in series of glioblastoma multiforme.

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elservier España, S.L. All rights reserved.
  • (PMID = 20492863.001).
  • [ISSN] 0213-4853
  • [Journal-full-title] Neurología (Barcelona, Spain)
  • [ISO-abbreviation] Neurologia
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


5. Iwami K, Arima T, Ooka F, Asai T, Tambara M, Takaoka T: [Bilateral thalamic glioma in an adult: a case report and review of the literature]. No Shinkei Geka; 2009 Mar;37(3):285-90
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of a 36-year-old woman who had a rare bilateral thalamic glioma (BTG).
  • Histological examination of the biopsy specimen identified diffuse astrocytoma (WHO grade II).
  • Death usually occurs within two years after onset, independently of adjuvant therapy such as radiotherapy and chemotherapy.
  • At the time of this writing (5 months after the consultation), there are no neurological symptoms, and no changes on neuroimaging.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Thalamus

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19306649.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 16
  •  go-up   go-down


6. Agrawal R: Synchronous dual malignancy: successfully treated cases. J Cancer Res Ther; 2007 Jul-Sep;3(3):153-6
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The occurrence of a second malignancy in a patient with a known malignant tumour is not uncommon.
  • HPE mastectomy specimen showed infiltrating duct carcinoma and stage II.
  • Patient was treated with external beam radiotherapy for carcinoma cervix and breast simultaneously and chemotherapy as required.
  • HPE brain tissue showed astrocytoma grade II and HPE parotid tumour showed low grade muco-epidermoid carcinoma.
  • Thus it was concluded that patients responded well to treatment.
  • Treatment strategies in case of synchronous double malignancy depend on treating the malignancy that is more advanced first or sometimes both could be treated simultaneously.
  • [MeSH-major] Astrocytoma / therapy. Brain Neoplasms / therapy. Breast Neoplasms / therapy. Carcinoma, Ductal, Breast / therapy. Carcinoma, Squamous Cell / therapy. Neoplasms, Multiple Primary / therapy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Treatment Outcome


7. Broniscer A, Gajjar A: Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist; 2004;9(2):197-206
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist.
  • Pediatric high-grade gliomas represent a heterogeneous group of tumors that accounts for 15%-20% of all pediatric central nervous system tumors.
  • These neoplasms predominantly involve the supratentorial hemispheres or the pons, in which case the tumors are usually called diffuse brainstem gliomas.
  • Older children (>3 years) with supratentorial neoplasms undergo a multimodality treatment comprised of surgical resection, radiation therapy, and chemotherapy.
  • The addition of chemotherapy seems to improve the survival of a subset of these children, particularly those with glioblastoma multiforme.
  • The diagnosis of a diffuse brainstem glioma is based upon typical imaging, dispensing with the need for surgery in the majority of cases.
  • Radiation therapy is the mainstay of treatment for children with diffuse brainstem gliomas.
  • The role of chemotherapy for these children is not clear, and it is, in general, employed in the context of an investigational study.
  • Less than 10% of children with diffuse brainstem gliomas survive 2 years.
  • Because the outcome for patients with either type of tumor is poor when standard multimodality therapy is used, these children are ideal candidates for innovative treatment approaches.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / therapy. Glioma / genetics. Glioma / therapy. Neoplasm Recurrence, Local
  • [MeSH-minor] Astrocytoma / physiopathology. Astrocytoma / therapy. Brain Stem Neoplasms / genetics. Brain Stem Neoplasms / physiopathology. Brain Stem Neoplasms / therapy. Child. Disease Progression. Humans. Prognosis. Treatment Outcome


8. Ramos Martínez A, Sánchez Romero I, Saura Lorente PA, Parajón Díaz A: [Suppurative thrombophlebitis central venous catheterization]. An Med Interna; 2008 Jun;25(6):284-6
Hazardous Substances Data Bank. CLOXACILLIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 22-year-old colombian-woman, student, without toxic habits was admitted because of temporary left astrocytoma (grade II).
  • The patient evolved satisfactorily with cloxacillin, gentamycin and low molecular weight heparin.
  • [MeSH-minor] Adult. Anti-Bacterial Agents / administration & dosage. Anti-Bacterial Agents / therapeutic use. Anticoagulants / administration & dosage. Anticoagulants / therapeutic use. Cloxacillin / administration & dosage. Cloxacillin / therapeutic use. Drug Therapy, Combination. Female. Follow-Up Studies. Gentamicins / administration & dosage. Gentamicins / therapeutic use. Heparin, Low-Molecular-Weight / administration & dosage. Heparin, Low-Molecular-Weight / therapeutic use. Humans. Neck / radiography. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • MedlinePlus Health Information. consumer health - Staphylococcal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19295976.001).
  • [ISSN] 0212-7199
  • [Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)
  • [ISO-abbreviation] An Med Interna
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anticoagulants; 0 / Gentamicins; 0 / Heparin, Low-Molecular-Weight; O6X5QGC2VB / Cloxacillin
  •  go-up   go-down


9. Nakasu S, Fukami T, Jito J, Matsuda M: Prognostic significance of loss of O6-methylguanine-DNA methyltransferase expression in supratentorial diffuse low-grade astrocytoma. Surg Neurol; 2007 Dec;68(6):603-8; discussion 608-9
Genetic Alliance. consumer health - Diffuse Astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of loss of O6-methylguanine-DNA methyltransferase expression in supratentorial diffuse low-grade astrocytoma.
  • If loss of function in MGMT is related to tumor progression, the immunohistochemical method may predict the malignant change of gliomas.
  • METHOD: We investigated the expression of MGMT by immunohistochemical method in 28 supratentorial hemispheric diffuse astrocytomas.
  • RESULTS: There were 19 MGMT-positive and 9 MGMT-negative astrocytomas.
  • Their rates of malignant transformation at 5 years were 12.3% and 51.4%, respectively.
  • Age, sex, extent of surgery, MIB-1 value, and radiation therapy at initial treatment did not correlate with the malignant progression.
  • Two long-term survivors with MGMT-negative tumor responded well to nitrosourea-based chemotherapy and lived more than 8 years after malignant transformation.
  • CONCLUSION: Although the status of MGMT did not affect the overall survival, immunohistochemical evaluation of MGMT expression may be a good marker for tumor progression.
  • [MeSH-major] Astrocytoma / metabolism. Astrocytoma / pathology. Biomarkers, Tumor / metabolism. O(6)-Methylguanine-DNA Methyltransferase / metabolism. Supratentorial Neoplasms / metabolism. Supratentorial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17825378.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


10. Nozaki M, Ohnishi A, Fujimaki T, Nagashima K, Cho K, Sawamura Y: Congenital gemistocytic astrocytoma in a fetus. Childs Nerv Syst; 2006 Feb;22(2):168-71
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital gemistocytic astrocytoma in a fetus.
  • This report presents a case of a congenital gemistocytic astrocytoma diagnosed by antenatal intrauterine ultrasound.
  • The patient was delivered by cesarean section and a total excision of the hemorrhagic tumor was carried out on the third day of his life.
  • The histological study revealed gemistocytic astrocytoma (WHO grade II).
  • Neither adjuvant chemotherapy nor radiation was given after the first surgery.
  • Ten months after his birth, a recurrent tumor was depicted on follow-up MRI.
  • The second total excision of the recurrent tumor and chemotherapy using cisplatin and vincristine were performed.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Fetus
  • [MeSH-minor] Adult. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry / methods. Ki-67 Antigen / metabolism. Magnetic Resonance Imaging / methods. Pregnancy. Synaptophysin / metabolism. Tomography, X-Ray Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Childs Nerv Syst. 1994 Mar;10(2):104-10 [8033157.001]
  • [Cites] AJR Am J Roentgenol. 1990 Sep;155(3):587-93 [2167004.001]
  • [Cites] J Neuropathol Exp Neurol. 1964 Apr;23:280-92 [14137675.001]
  • [Cites] Childs Nerv Syst. 1997 Oct;13(10 ):556-9 [9403206.001]
  • [Cites] Neuroradiology. 1982;23 (5):267-74 [7121821.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(12):1213-22 [9932120.001]
  • [Cites] J Neurosurg. 1988 Oct;69(4):604-9 [3047342.001]
  • [Cites] Lab Invest. 1997 Feb;76(2):277-84 [9042164.001]
  • [Cites] J Neurosurg. 1991 Mar;74(3):399-406 [1993905.001]
  • [Cites] Brain Pathol. 2004 Apr;14(2):227-8 [15193038.001]
  • [Cites] Surg Neurol. 1984 Jun;21(6):597-609 [6372141.001]
  • [Cites] P R Health Sci J. 2002 Mar;21(1):43-5 [12013680.001]
  • [Cites] Fetal Diagn Ther. 2003 May-Jun;18(3):137-9 [12711864.001]
  • [Cites] Childs Brain. 1981;8(4):263-70 [7261690.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):171-8 [10758320.001]
  • [Cites] Med Pediatr Oncol. 1994;22(5):309-17 [8127254.001]
  • [Cites] Childs Nerv Syst. 1999 Apr;15(4):197-201 [10361971.001]
  • [Cites] Cancer. 1985 Sep 1;56(5):1106-11 [2990664.001]
  • [Cites] Pediatr Neurosurg. 2002 Nov;37(5):267-70 [12411720.001]
  • [Cites] Childs Nerv Syst. 2000 Aug;16(8):501-2 [11007501.001]
  • [Cites] J Neurosurg. 1951 May;8(3):315-9 [14841542.001]
  • [Cites] J Neurooncol. 1998 May;37(3):263-70 [9524084.001]
  • [Cites] Ultrasound Obstet Gynecol. 1995 Jan;5(1):63-6 [7850596.001]
  • (PMID = 15864706.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / Synaptophysin
  •  go-up   go-down


11. Nakamura M, Tsuji O, Fujiyoshi K, Watanabe K, Tsuji T, Ishii K, Matsumoto M, Toyama Y, Chiba K: Cordotomy for patients with thoracic malignant astrocytoma. J Neurosurg Spine; 2010 Oct;13(4):418-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cordotomy for patients with thoracic malignant astrocytoma.
  • OBJECT: The optimal management of malignant astrocytomas remains controversial, and the prognosis of these lesions has been dismal regardless of the administered treatment.
  • In this study the authors investigated the surgical outcomes of cordotomy in patients with thoracic malignant astrocytomas to determine the effectiveness of this procedure.
  • METHODS: Cordotomy was performed in 5 patients with glioblastoma multiforme (GBM) and 2 with anaplastic astrocytoma (AA).
  • In the 2 patients with GBM, cordotomy was performed 2 and 3 weeks after a partial tumor resection.
  • In the 2 patients with AA, the initial treatment consisted of partial tumor resection and subtotal resection combined with radiotherapy, and rostral tumor growth and progressive paralysis necessitated cordotomy 2 and 28 months later.
  • One patient with a secondary GBM underwent cordotomy; the GBM developed 1 year after subtotal resection and radiotherapy for a WHO Grade II astrocytoma.
  • Four patients died 4, 5, 24, and 42 months after the initial operation due to CSF dissemination, and 3 patients (2 with GBM and 1 with AA) remain alive (16, 39, and 71 months).
  • In patients with thoracic GBM, even if paralysis is incomplete, cordotomy should be performed before the tumor disseminates through the CSF.
  • If the tumor persists, radiotherapy and chemotherapy are indicated, and cordotomy should be reserved for lesions growing progressively after such second-line treatments.
  • [MeSH-major] Astrocytoma / surgery. Cordotomy. Thoracic Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Disease Progression. Encephalitis / etiology. Female. Glioblastoma / complications. Glioblastoma / pathology. Glioblastoma / surgery. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Pain, Postoperative. Paraplegia / etiology. Paraplegia / surgery. Prognosis. Radiotherapy, Adjuvant. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20887138.001).
  • [ISSN] 1547-5646
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Weber MA, Vogt-Schaden M, Bossert O, Giesel FL, Kauczor HU, Essig M: [MR perfusion and spectroscopic imaging in WHO grade II astrocytomas]. Radiologe; 2007 Sep;47(9):812-8
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [MR perfusion and spectroscopic imaging in WHO grade II astrocytomas].
  • [Transliterated title] MR-Perfusions- und spektroskopische Bildgebung bei WHO-Grad-II-Astrozytomen.
  • BACKGROUND: This study evaluates whether MR perfusion imaging and spectroscopic imaging (MRSI) can depict anaplastic areas in WHO grade II astrocytomas, whether these areas are co-localized, and whether the prognosis can be better predicted.
  • MATERIAL AND METHODS: Fifteen patients (nine female, six male, aged 42+/-14 years) with WHO grade II astrocytomas but without preceding radio- or chemotherapy were examined every 3 months with MR perfusion imaging and MRSI (mean follow-up 18 months).
  • Using a region of interest analysis, the regional relative cerebral blood volume (rrCBV) and blood flow (rrCBF) were measured in tumor tissue.
  • In six patients, the tumor showed progression and contrast-enhancement.
  • The progressing tumors had already had higher perfusion (rrCBF 2.1+/-1.4; rrCBV 1.9+/-1.1) parameters than the stable astrocytomas (rrCBF 1.2+/-0.6, p=0.01; rrCBV 1.4+/-0.8, p=0.05) at first examination.
  • However, the Cho/NAA and Cho/Cr ratios only tended to be higher than in stable astrocytomas (Cho/NAA 2.4+/-1.0 vs. 2.0+/-1.5, p=0.23; Cho/Cr 1.7+/-0.6 vs. 1.4+/-0.5, p=0.06).
  • CONCLUSIONS: MR perfusion imaging can depict anaplastic areas in WHO grade II astrocytomas earlier than conventional MRI and thus enables a better prediction of prognosis.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Magnetic Resonance Imaging. Magnetic Resonance Spectroscopy
  • [MeSH-minor] Adult. Brain / pathology. Data Interpretation, Statistical. Disease Progression. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Prospective Studies. Time Factors. World Health Organization

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2001 Aug;22(7):1316-24 [11498420.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):996-1003 [14575830.001]
  • [Cites] Eur Radiol. 2004 Apr;14(4):679-85 [14610685.001]
  • [Cites] Australas Radiol. 2001 Nov;45(4):472-82 [11903181.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Feb;25(2):214-21 [14970020.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1 [10200775.001]
  • [Cites] Radiology. 2002 Apr;223(1):11-29 [11930044.001]
  • [Cites] AJR Am J Roentgenol. 1998 Dec;171(6):1479-86 [9843274.001]
  • [Cites] Magn Reson Med. 1996 Nov;36(5):715-25 [8916022.001]
  • [Cites] J Neurosurg. 1993 Oct;79(4):533-6 [8410222.001]
  • [Cites] Neuroradiology. 2005 Nov;47(11):826-34 [16142479.001]
  • [Cites] Radiology. 2006 Feb;238(2):658-67 [16396838.001]
  • [Cites] Neurosci Lett. 2003 May 22;342(3):163-6 [12757890.001]
  • [Cites] Radiologe. 2000 Oct;40(10):849-57 [11103407.001]
  • [Cites] Magn Reson Med. 1996 Nov;36(5):726-36 [8916023.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):478-82 [11567824.001]
  • [Cites] Invest Radiol. 2004 May;39(5):277-87 [15087722.001]
  • [Cites] Surg Neurol. 1998 Apr;49(4):436-40 [9537664.001]
  • [Cites] Radiology. 1994 Apr;191(1):41-51 [8134596.001]
  • [Cites] Rofo. 1999 Jul;171(1):38-43 [10464503.001]
  • [Cites] Radiology. 2003 Aug;228(2):523-32 [12819338.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98 [14625221.001]
  • [Cites] Lancet Neurol. 2005 Nov;4(11):760-70 [16239183.001]
  • [Cites] Nat Med. 1996 Mar;2(3):323-5 [8612232.001]
  • [Cites] Radiologe. 2002 Nov;42(11):909-15 [12458444.001]
  • [Cites] Radiologe. 2005 Jul;45(7):618-32 [15098092.001]
  • (PMID = 16924439.001).
  • [ISSN] 0033-832X
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Combs SE, Ahmadi R, Schulz-Ertner D, Thilmann C, Debus J: Recurrent low-grade gliomas: the role of fractionated stereotactic re-irradiation. J Neurooncol; 2005 Feb;71(3):319-23
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent low-grade gliomas: the role of fractionated stereotactic re-irradiation.
  • PURPOSE: To assess the effectiveness of re-irradiation in recurrent low-grade gliomas (LGG).
  • At primary diagnosis of the tumor, the histology was grade II astrocytoma, oligodendroglioma or oligoastrocytoma.
  • Using three to four irregular non-coplanar fields formed with a multi-leaf-collimator, we applied a median total dose of 36 Gy (range 15-62 Gy)with a weekly fractionation of 5 x 2 Gy/week depending on the size and the location of the lesion.
  • No concomitant chemotherapy was applied.
  • Median interval between the first radiation therapy and re-irradiation was 50 months (range 5-204 months).
  • From the time point of re-irradiation, median survival was 23 months.
  • Median progression-free survival from the time point of re-irradiation was 12 months (range 2-63 months).
  • CONCLUSION: Our retrospective data suggest that stereotactically guided fractionated re-irradiation in recurrent glioma represents an effective treatment option with good results and few complications.
  • However, further investigation is warranted to consolidate these results and to combine radiation with chemotherapy in the case of recurrent LGG.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Dose Fractionation. Glioma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Radiotherapy / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):996-1003 [14575830.001]
  • [Cites] Cancer. 1993 Jul 1;72 (1):190-5 [8508405.001]
  • [Cites] Eur J Cancer. 1998 Jan;34(1):98-102 [9624245.001]
  • [Cites] Cancer. 1994 Sep 15;74(6):1784-91 [8082081.001]
  • [Cites] Semin Radiat Oncol. 2001 Apr;11(2):145-51 [11285552.001]
  • [Cites] Arch Neurol. 1989 Nov;46(11):1238-9 [2818260.001]
  • [Cites] Arch Neurol. 1990 Oct;47(10):1138-40 [2222248.001]
  • [Cites] Cancer. 1985 Mar 1;55(5):919-27 [3967199.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1998 May;64(5):581-7 [9598670.001]
  • [Cites] Br J Cancer. 2003 Jul 21;89(2):232-8 [12865907.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2267-76 [11980997.001]
  • [Cites] J Neurosurg. 1989 Jun;70(6):853-61 [2715812.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1405-9 [2542195.001]
  • [Cites] Semin Oncol. 1994 Apr;21(2):236-48 [8153667.001]
  • [Cites] Can J Surg. 1993 Jun;36(3):271-5 [8391917.001]
  • [Cites] Radiother Oncol. 2000 Nov;57(2):215-23 [11054526.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):393-8 [9069312.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1294-301 [9193320.001]
  • [Cites] Neurology. 2000 Apr 11;54(7):1402-3 [10751245.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):646-51 [12586801.001]
  • [Cites] Radiologe. 1995 Sep;35(9):583-6 [8588040.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):719-27 [8040017.001]
  • [Cites] J Neurosurg. 1984 Oct;61(4):665-73 [6470776.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12 ):2305-11 [12805331.001]
  • [Cites] Neurosurgery. 1987 Nov;21(5):615-21 [2827052.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1133-41 [10613305.001]
  • [Cites] J Neurosurg. 1993 Jun;78(6):909-14 [8487073.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):370-9 [9010111.001]
  • [Cites] Oncology. 2000 Feb;58(2):108-16 [10705237.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):977-82 [10192343.001]
  • [Cites] Neurology. 1999 Sep 22;53(5):1141-3 [10496285.001]
  • [Cites] Ann Oncol. 2003 Apr;14 (4):599-602 [12649108.001]
  • [Cites] Semin Surg Oncol. 2001 Jan-Feb;20(1):13-23 [11291128.001]
  • [Cites] Semin Oncol. 2003 Dec;30(6 Suppl 19):10-4 [14765378.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):291-6 [8795601.001]
  • [Cites] Neurology. 2000 Apr 11;54(7):1442-8 [10751254.001]
  • [Cites] Clin Neurosurg. 1995;42:488-94 [8846613.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):316-24 [11872276.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • [Cites] Neurosurgery. 1996 May;38(5):872-8; discussion 878-9 [8727811.001]
  • [Cites] Radiology. 1996 Oct;201(1):275-8 [8816559.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1937-45 [8137221.001]
  • (PMID = 15735924.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Passarin MG, Moretto G, Musso AM, Ottaviani S, Masotto B, Ghimenton C, Iuzzolino P, Buffone E, Rudà R, Soffietti R, Vattemi E, Pedersini R: Intrathecal liposomal cytarabine in combination with temozolomide in low-grade oligoastrocytoma with leptomeningeal dissemination. J Neurooncol; 2010 May;97(3):439-44
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrathecal liposomal cytarabine in combination with temozolomide in low-grade oligoastrocytoma with leptomeningeal dissemination.
  • Leptomeningeal dissemination of low-grade gliomas is an uncommon event.
  • A nonenhancing lesion in the right cerebellar peduncle was identified, subtotally resected, and diagnosed as a grade II astrocytoma.
  • After one year a nodular spread in the brain and leptomeninges was diagnosed, so the patient started chemotherapy with temozolomide and liposomal cytarabine.
  • Complete remission was achieved after 12 months of treatment and the patient is still free from the disease after a follow-up of 24 months.
  • We suggest that this combination may be a valuable treatment option.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Cytarabine / therapeutic use. Dacarbazine / analogs & derivatives. Meningeal Neoplasms / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Injections, Spinal / methods. Liposomes / administration & dosage. Magnetic Resonance Imaging / methods. Male

  • Genetic Alliance. consumer health - Oligoastrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3133-8 [15284265.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):253-60 [12356355.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10 (11):3728-36 [15173079.001]
  • [Cites] J Neurooncol. 2002 May;57(3):231-9 [12125986.001]
  • [Cites] Ann Pharmacother. 2000 Oct;34(10):1173-8 [11054987.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):646-51 [12586801.001]
  • [Cites] Arch Neurol. 1995 Sep;52(9):912-7 [7661730.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3605-13 [15908671.001]
  • [Cites] Ann Oncol. 2003 Dec;14 (12 ):1715-21 [14630674.001]
  • [Cites] Clin Neurol Neurosurg. 2009 May;111(4):390-4 [19128871.001]
  • [Cites] Acta Neurochir (Wien). 1994;126(2-4):84-92 [8042560.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3394-402 [10589750.001]
  • [Cites] J Neurooncol. 2007 Jul;83(3):303-6 [17245619.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2869-78 [8194029.001]
  • [Cites] Oncologist. 2006 Jun;11(6):681-93 [16794247.001]
  • (PMID = 19876600.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Liposomes; 04079A1RDZ / Cytarabine; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  •  go-up   go-down


15. Bristol RE: Low-grade glial tumors: are they all the same? Semin Pediatr Neurol; 2009 Mar;16(1):23-6
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade glial tumors: are they all the same?
  • The most common diagnosis for supratentorial brain tumors in children is a form of low-grade glioma.
  • Even though the numbers of any given tumor type are small, the question has been raised as to whether different pathologies require different treatments.
  • We reviewed the published articles on treatment and outcomes for all pathologies included under the heading "low-grade glioma" to answer this question.
  • Once intervention is deemed necessary, attempted complete surgical resection remains the mainstay of treatment for all diagnoses.
  • Unresectable residuals or recurrences can be treated with adjuvant therapies.
  • The only pathologic subgroups that may benefit from more aggressive up-front treatment are the grade II astrocytomas.
  • Radiation is reserved for older children, and chemotherapy protocols are favored in younger children.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Glioma / diagnosis. Glioma / therapy
  • [MeSH-minor] Astrocytoma / diagnosis. Astrocytoma / therapy. Chemotherapy, Adjuvant. Child. Ganglioglioma / diagnosis. Ganglioglioma / therapy. Humans. Oligodendroglioma / diagnosis. Oligodendroglioma / therapy. Radiotherapy, Adjuvant. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19410153.001).
  • [ISSN] 1558-0776
  • [Journal-full-title] Seminars in pediatric neurology
  • [ISO-abbreviation] Semin Pediatr Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 31
  •  go-up   go-down


16. Watanabe T, Komine C, Yokoyama T, Yoshino A, Katayama Y: [Therapeutic efficacy and prognostic factors in diffuse astrocytomas]. No Shinkei Geka; 2003 Jul;31(7):767-73
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic efficacy and prognostic factors in diffuse astrocytomas].
  • Diffuse astrocytomas are slowly growing tumors with a relatively long overall survival.
  • Considerable controversy exists as to the best therapeutic management for patients with such tumors.
  • In the present study, we retrospectively analyzed a series of 64 patients with WHO grade II astrocytomas of the cerebral hemispheres.
  • Gross total resection and interferon-beta therapy were significantly associated with both longer progression free survival (PFS) and overall survival (OS).
  • Immediate postoperative radiation therapy did not prolong either the PFS or OS.
  • Our data suggest that radical surgery plus interferon-beta therapy may offer the best chance for long survival.
  • Since the presence of MGMT methylation is a probable indication of an increased sensitivity to alkylating chemotherapeutic agents, determining the methylation status of MGMT could provide a potential basis for logical therapeutic intervention in identifying a subgroup of patients who could be candidates for early chemotherapy.
  • [MeSH-major] Astrocytoma / therapy. Brain Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Interferon-beta / therapeutic use. Male. Methylation. Middle Aged. Neurosurgical Procedures. O(6)-Methylguanine-DNA Methyltransferase / genetics. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12884791.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 77238-31-4 / Interferon-beta; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


17. Soffietti R, Baumert BG, Bello L, von Deimling A, Duffau H, Frénay M, Grisold W, Grant R, Graus F, Hoang-Xuan K, Klein M, Melin B, Rees J, Siegal T, Smits A, Stupp R, Wick W, European Federation of Neurological Societies: Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol; 2010 Sep;17(9):1124-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force.
  • BACKGROUND: Diffuse infiltrative low-grade gliomas of the cerebral hemispheres in the adult are a group of tumors with distinct clinical, histological and molecular characteristics, and there are still controversies in management.
  • RESULTS AND CONCLUSIONS: WHO classification recognizes grade II astrocytomas, oligodendrogliomas and oligoastrocytomas.
  • Conventional MRI is used for differential diagnosis, guiding surgery, planning radiotherapy and monitoring treatment response.
  • Prophylactic antiepileptic drugs are not useful, whilst there is no evidence that one drug is better than the others.
  • Total/near total resection can improve seizure control, progression-free and overall survival, whilst reducing the risk of malignant transformation.
  • Low doses of radiation are as effective as high doses and better tolerated.
  • Chemotherapy can be useful both at recurrence after radiotherapy and as initial treatment after surgery to delay the risk of late neurotoxicity from large-field radiotherapy.
  • Neurocognitive deficits are frequent and can be caused by the tumor itself, tumor-related epilepsy, treatments and psychological distress.
  • [MeSH-major] Advisory Committees / trends. Antineoplastic Protocols / standards. Glioma / therapy
  • [MeSH-minor] Cognition Disorders / drug therapy. Cognition Disorders / etiology. Cognition Disorders / surgery. Combined Modality Therapy / methods. Combined Modality Therapy / standards. Europe. Evidence-Based Medicine / trends. Humans. Neoplasm Metastasis / diagnosis. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / radiotherapy. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Neurosurgical Procedures / methods. Neurosurgical Procedures / standards. Prognosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20718851.001).
  • [ISSN] 1468-1331
  • [Journal-full-title] European journal of neurology
  • [ISO-abbreviation] Eur. J. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] England
  •  go-up   go-down


18. Komine C, Watanabe T, Katayama Y, Yoshino A, Yokoyama T, Fukushima T: Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol; 2003 Apr;13(2):176-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas.
  • In several human neoplasms including low-grade diffuse astrocytomas, promoter hypermethylation of MGMT has been shown to correlate with an increased frequency of p53 mutation.
  • In the present study, we analyzed MGMT promoter methylation by the methylation-specific PCR in 49 newly diagnosed WHO grade II astrocytomas and evaluated its clinical usefulness.
  • The presence of MGMT methylation was significantly associated with a shorter progression free survival (PFS) on both univariate analysis (P=0.0014) and multivariate analysis (P=0.0081).
  • The present findings indicate that aberrant methylation of the MGMT promoter independently augurs for an unfavorable clinical course in patients with low-grade diffuse astrocytomas.
  • Since the presence of MGMT methylation is expected to predict an increased sensitivity to alkylating chemotherapeutic agents, earlier chemotherapy could serve to improve an unfavorable natural history in tumors with MGMT methylation.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. DNA Methylation. Neoplasm Recurrence, Local / genetics. O(6)-Methylguanine-DNA Methyltransferase / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12744471.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


19. Cannon GM, Tomé WA, Robins HI, Howard SP: Pulsed reduced dose-rate radiotherapy: case report : a novel re-treatment strategy in the management of recurrent glioblastoma multiforme. J Neurooncol; 2007 Jul;83(3):307-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulsed reduced dose-rate radiotherapy: case report : a novel re-treatment strategy in the management of recurrent glioblastoma multiforme.
  • The initial management of malignant gliomas is multimodality in nature, consisting of surgery, radiation therapy and chemotherapy.
  • However, once progression has occurred, treatment options are limited both in terms of selection and efficacy.
  • We report a case of a 37 year-old male diagnosed with a Grade II astrocytoma initially treated with surgery and external beam radiation therapy consisting of 54 Gy delivered in 1.8 Gy fractions that subsequently progressed to a Grade IV astrocytoma.
  • This was managed with temozolomide chemotherapy until the patient exhibited further progression.
  • This reduction in dose-rate is obtained by delivering treatment in a series of 0.2 Gy pulses separated by 3 min time intervals, creating an apparent dose rate of 0.0667 Gy/min.
  • The region of recurrence was treated to a dose of 50 Gy delivered using 25 daily fractions of 2.0 Gy.
  • The patient had both a radiographic response and clinical improvement following re-irradiation using pulsed reduced dose-rate radiotherapy with no apparent acute or late neurologic toxicities at a time when other treatment options were not available.
  • Despite delivering 104 Gy to the tumor bed and the surrounding brain parenchyma, at no time was there radiographic evidence of radiation-induced normal tissue necrosis.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Glioblastoma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adult. Dose Fractionation. Humans. Magnetic Resonance Imaging. Male. Radiotherapy Dosage. Retreatment. Salvage Therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] Neuro Oncol. 1999 Oct;1(4):282-8 [11550320.001]
  • [Cites] Neurosurgery. 1987 Aug;21(2):201-6 [2821446.001]
  • [Cites] Radiother Oncol. 2001 May;59(2):127-37 [11325440.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Dec;19(6):1397-403 [2262364.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]
  • [Cites] Clin Neurol Neurosurg. 1997 May;99(2):117-23 [9213056.001]
  • [Cites] Cancer. 2004 Feb 1;100(3):605-11 [14745879.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Mar;11(3):431-9 [3972657.001]
  • [Cites] Br J Radiol. 2007 Jan;80(949):32-7 [16945935.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Sep 1;36(2):433-41 [8892469.001]
  • [Cites] Curr Treat Options Oncol. 2002 Dec;3(6):509-24 [12392640.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1273-80 [16525182.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] Neurosurgery. 1994 Feb;34(2):213-9; discussion 219-20 [8177380.001]
  • (PMID = 17252184.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Scott IS, Morris LS, Rushbrook SM, Bird K, Vowler SL, Burnet NG, Coleman N: Immunohistochemical estimation of cell cycle entry and phase distribution in astrocytomas: applications in diagnostic neuropathology. Neuropathol Appl Neurobiol; 2005 Oct;31(5):455-66
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical estimation of cell cycle entry and phase distribution in astrocytomas: applications in diagnostic neuropathology.
  • An immunohistochemical method for assessing cell cycle phase distribution in neurosurgical biopsies would enable such data to be incorporated into diagnostic algorithms for the estimation of prognosis and response to adjuvant chemotherapy in glial neoplasms, without the requirement for flow cytometric analysis.
  • Paraffin-embedded sections of intracerebral gliomas (n = 48), consisting of diffuse astrocytoma (n = 9), anaplastic astrocytoma (n = 8) and glioblastoma (n = 31), were analysed by immunohistochemistry using markers of cell cycle entry, Mcm-2 and Ki67, and putative markers of cell cycle phase, cyclins D1 (G1-phase), cyclin A (S-phase), cyclin B1 (G2-phase) and phosphohistone H3 (Mitosis).
  • There was a significant increase in Mcm-2 (P < 0.0001), Ki67 (P < 0.0001), cyclin A (P < 0.0001) and cyclin B1 (P = 0.002) expression with increasing grade from diffuse astrocytoma through anaplastic astrocytoma to glioblastoma, suggesting that any of these four markers has potential as a marker of tumour grade.
  • We conclude that it is feasible to obtain detailed cell cycle data by immunohistochemical analysis of tissue biopsies.
  • [MeSH-major] Astrocytoma / pathology. Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Cell Cycle / physiology. Immunohistochemistry / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16150117.001).
  • [ISSN] 0305-1846
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CCNB1 protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin A; 0 / Cyclin B; 0 / Cyclin B1; 0 / Histones; 136601-57-5 / Cyclin D1
  •  go-up   go-down


21. Sakata K, Hareyama M, Komae T, Shirato H, Watanabe O, Watarai J, Takai K, Yamada S, Tsuchida E, Sakai K: Supratentorial astrocytomas and oligodendrogliomas treated in the MRI era. Jpn J Clin Oncol; 2001 Jun;31(6):240-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supratentorial astrocytomas and oligodendrogliomas treated in the MRI era.
  • BACKGROUND: There is at present no consensus on the policy for the treatment of patients with low-grade gliomas (LGGs).
  • METHODS: This report is a retrospective multi-institutional study of 100 patients (ages 16-65 years) with astrocytoma (grade II), oligodendroglioma, anaplastic oligodendroglioma and anaplastic oligoastrocytoma of the supratentorial areas which were treated with surgery and postoperative radiotherapy at five university hospitals in northern Japan between 1990 and 1997 when MRI was routinely used to determine the target volume.
  • Most patients were irradiated with 50-60 Gy.
  • The target volume usually covered the areas with T2 prolongation of MRI with a margin of 2 cm.
  • RESULTS: The disease-specific 5-year survival rate was 87.4% for patients with oligodendroglioma and 75.3% for patients with astrocytoma.
  • Survival for patients with astrocytoma in the MRI era appears to be improved compared with historical controls in the literature.
  • Patients with astrocytoma aged 40 years and under had a significantly better disease-specific survival rate than those over 40 years (P < 0.05) and patients with oligodendroglioma and oligoastrocytoma showed a similar tendency.
  • Patients with astrocytoma who had over 50% of their tumor removed had a significantly better survival rate than those who had less than 50% removed (P < 0.05).
  • Chemotherapy appeared to improve the disease-specific survival rate of patients with oligodendroglioma but not that of patients with astrocytoma.
  • CONCLUSION: Oligodendroglioma has a more protracted course of disease progression than astrocytoma.
  • This particular feature and the sensitivity of LGGs to chemotherapy as well as their relevant prognostic factors, such as age, histopathology and amount of tumor removal, should be taken into account before any decision on treatment methods for LGGs is made.
  • [MeSH-major] Astrocytoma / radiotherapy. Oligodendroglioma / radiotherapy. Supratentorial Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Radiotherapy Dosage. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11463800.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Japan
  •  go-up   go-down


22. Nakamura M, Shimada K, Nakase H, Konishi N: [Clinicopathological diagnosis of gliomas by genotype analysis]. Brain Nerve; 2009 Jul;61(7):773-80
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastomas (WHO grade IV) may develop de novo (primary glioblastomas) or through progression from lower-grade astrocytomas (secondary glioblastomas) both glioblastomas show similar histological features.
  • However, these subtypes of glioblastoma involve distinct disease entities that evolve through different genetic pathways and are likely to differ in prognosis and response to therapy.
  • Oligodendroglioma is recognized as a particular subtype of gliomas that shows remarkable response to chemotherapy [procarbazine+CCNU+vincristine (PCV)], making their correct diagnosis important.
  • However, the histological differentiation of oligodendrogliomas from diffuse astrocytoma could be highly subjective in cases without typical morphological features.
  • Loss of heterozygosity (LOH) on chromosomes 1p and 19q is correlated with sensitivity to PCV chemotherapy with increased survival in anaplastic oligodendroglioma cases (WHO grade III).
  • We have previously found methylation or expression mosaicism of O6-MGMT in gliomas, resulting in problems on tumor sampling and response to TMZ.
  • This article suggests that more biological and molecular approaches to brain tumor classification will provide improved means to treat these tumors.
  • [MeSH-minor] Antineoplastic Agents, Alkylating. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Dacarbazine / analogs & derivatives. Humans. Lomustine / administration & dosage. Loss of Heterozygosity. Pharmacogenetics. Procarbazine / administration & dosage. Prognosis. Tumor Suppressor Proteins / genetics. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19618854.001).
  • [ISSN] 1881-6096
  • [Journal-full-title] Brain and nerve = Shinkei kenkyū no shinpo
  • [ISO-abbreviation] Brain Nerve
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Suppressor Proteins; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes; PCV protocol
  • [Number-of-references] 42
  •  go-up   go-down


23. Mukasa A, Ueki K, Ge X, Ishikawa S, Ide T, Fujimaki T, Nishikawa R, Asai A, Kirino T, Aburatani H: Selective expression of a subset of neuronal genes in oligodendroglioma with chromosome 1p loss. Brain Pathol; 2004 Jan;14(1):34-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, more objective diagnostic criteria are indispensable for the precise treatment of patients.
  • For instance, loss of the short arm of chromosome 1 (1p) in oligodendrogliomas is recognized as an important marker for better response to chemotherapy and longer survival of the patients.
  • To gain insight into their molecular biological background and to identify genes characterizing each subgroup, we investigated gene expression profile of the 4 glioma subsets, oligodendroglioma with and without 1p loss, diffuse astrocytoma and glioblastoma using DNA microarray.
  • Remarkably, most of the genes showing distinctive expression in oligodendroglioma with 1p loss were also highly expressed in normal brain tissues and had neuron-related function, which included MYT1L, INA, RIMS2, SNAP97 and SNCB.
  • Histological analysis also demonstrated that MYT1L, which were abundantly expressed in normal neuron, were certainly present in tumor cells.
  • [MeSH-minor] Astrocytoma / genetics. Chromosomes, Human, Pair 1 / genetics. Gene Expression Profiling. Glioblastoma / genetics. Humans. Immunohistochemistry. In Situ Hybridization. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14997935.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


24. Osoba AO, Kutub H, Waliuddin A, Sharab MO: Enterococcus avium. An unusual cause of cerebral abscess. Neurosciences (Riyadh); 2005 Oct;10(4):297-300

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we report a 19-year-old Saudi girl diagnosed as a case of astrocytoma grade II arising from the right thalamus.
  • She underwent treatment with radiotherapy followed by 5 chemotherapy sessions.
  • She subsequently developed a cerebral abscess, and we performed mini craniotomy of the left parietal region with drainage of the brain abscess.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22473142.001).
  • [ISSN] 1319-6138
  • [Journal-full-title] Neurosciences (Riyadh, Saudi Arabia)
  • [ISO-abbreviation] Neurosciences (Riyadh)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


25. Gimenez M, Souza VC, Izumi C, Barbieri MR, Chammas R, Oba-Shinjo SM, Uno M, Marie SK, Rosa JC: Proteomic analysis of low- to high-grade astrocytomas reveals an alteration of the expression level of raf kinase inhibitor protein and nucleophosmin. Proteomics; 2010 Aug;10(15):2812-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of low- to high-grade astrocytomas reveals an alteration of the expression level of raf kinase inhibitor protein and nucleophosmin.
  • These proteins are not only potential disease biomarkers, but also targets for therapy.
  • The aim of this study was to identify differentially expressed proteins in diffuse astrocytoma grade II, anaplastic astrocytoma grade III and glioblastoma multiforme grade IV in human tumor samples and in non-neoplastic brain tissue as control using 2-DE and MS.
  • Tumor and control brain tissue dissection was guided by histological hematoxylin/eosin tissue sections to provide more than 90% of tumor cells and astrocytes.
  • Six proteins were detected as up-regulated in higher grade astrocytomas and the most important finding was nucleophosmin (NPM) (p<0.05), whereas four proteins were down-regulated, among them raf kinase inhibitor protein (RKIP) (p<0.05).
  • We report here for the first time the alteration of NPM and RKIP expression in brain cancer.
  • The proteomic data for NPM and RKIP were confirmed by Western blot, quantitative real-time PCR and immunohistochemistry.
  • Due to the participation of NPM and RKIP in uncontrolled proliferation and evasion of apoptosis, these proteins are likely targets for drug development.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Nuclear Proteins / genetics. Phosphatidylethanolamine Binding Protein / genetics. Proteomics


26. Watanabe T, Katayama Y, Yoshino A, Komine C, Yokoyama T, Fukushima T: Treatment of low-grade diffuse astrocytomas by surgery and human fibroblast interferon without radiation therapy. J Neurooncol; 2003 Jan;61(2):171-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of low-grade diffuse astrocytomas by surgery and human fibroblast interferon without radiation therapy.
  • Low-grade diffuse astrocytomas are slowly growing tumors with a relatively long overall survival.
  • However, a substantial proportion undergoes dedifferentiation to a more malignant phenotype.
  • Considerable controversy exists as to the best therapeutic management for patients with such tumors.
  • Over the past decade, we have applied human fibroblast interferon (HFIF) therapy without radiation therapy to low-grade astrocytomas.
  • We investigated 28 patients with WHO grade II astrocytomas of the cerebral hemispheres treated by surgery plus HFIF therapy.
  • The overall response rate to the HFIF therapy was 36%.
  • Although our data from small cohort of patients may have modest value, our results suggest that HFIF may be useful in treating low-grade diffuse astrocytomas.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / surgery. Brain Neoplasms / drug therapy. Brain Neoplasms / surgery. Interferon-beta / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Cohort Studies. Combined Modality Therapy. Female. Fibroblasts / metabolism. Humans. Magnetic Resonance Imaging. Male. Maximum Tolerated Dose. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurochir (Wien). 1994;127(1-2):55-9 [7942182.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):6-14 [2354409.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Oct;15(4):837-41 [3141317.001]
  • [Cites] Semin Radiat Oncol. 2001 Apr;11(2):138-44 [11285551.001]
  • [Cites] Semin Radiat Oncol. 2001 Apr;11(2):145-51 [11285552.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jun 1;35(3):527-33 [8655376.001]
  • [Cites] Neurosurgery. 1991 Apr;28(4):496-501 [1851971.001]
  • [Cites] Neurosurgery. 1993 Apr;32(4):554-9 [8474646.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1998 May;64(5):581-7 [9598670.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3129-40 [9294476.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):923-9 [10571199.001]
  • [Cites] J Neurosurg. 2001 Nov;95(5):735-45 [11702861.001]
  • [Cites] J Neurosurg. 1989 Jun;70(6):853-61 [2715812.001]
  • [Cites] Neurosurgery. 1992 Oct;31(4):636-42; discussion 642 [1407448.001]
  • [Cites] Neurosurg Focus. 1998 Jun 15;4(6):e10 [17154440.001]
  • [Cites] J Clin Neurosci. 2001 May;8(3):253-5 [11386801.001]
  • [Cites] Clin Cancer Res. 1997 Mar;3(3):381-7 [9815695.001]
  • [Cites] J Neurooncol. 2000 Aug;49(1):57-62 [11131987.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1294-301 [9193320.001]
  • [Cites] Int J Cancer. 1987 Sep 15;40(3):365-71 [3497883.001]
  • [Cites] Neurosurgery. 1998 Apr;42(4):724-9 [9574635.001]
  • [Cites] J Neurosurg. 1993 Jun;78(6):909-14 [8487073.001]
  • [Cites] Oncology. 2000 Feb;58(2):108-16 [10705237.001]
  • [Cites] Neuro Oncol. 1999 Jan;1(1):44-51 [11550301.001]
  • [Cites] J Clin Oncol. 1995 Sep;13(9):2263-71 [7666084.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):291-6 [8795601.001]
  • [Cites] Acta Oncol. 1999;38(8):1051-6 [10665762.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):316-24 [11872276.001]
  • [Cites] Virchows Arch. 1995;427(2):113-8 [7582239.001]
  • [Cites] Neurosurgery. 1996 May;38(5):872-8; discussion 878-9 [8727811.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1937-45 [8137221.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1988 Jan;51(1):50-9 [2832547.001]
  • (PMID = 12622456.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 77238-31-4 / Interferon-beta
  •  go-up   go-down


27. Yamada SM, Hayashi Y, Takahashi H, Teramoto A, Matsumoto K, Yamada S: Histological and genetic diagnosis of gliomatosis cerebri: case report. J Neurooncol; 2001 May;52(3):237-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomatosis cerebri is considered grade III astrocytoma because of the short survival period of patients with this tumor, while the tumor histologically consists of widespread low grade astrocytoma cells.
  • The authors tried to clarify this discrepancy by applying genetic analysis of the tumor.
  • A 29-year-old man originally presented with mild headache and showed diffuse high intensity areas in both hemispheres and in the cerebellum by T2-weighted magnetic resonance imaging (MRI) without gadolinium-dimeglumine (Gd)-enhancement in T1-weighted imaging.
  • Histological diagnosis was gliomatosis cerebri with diffuse grade II astrocytoma.
  • Seven months after temporary improvement following irradiation and chemotherapy, he developed progressive mental deterioration, and died in one year after the surgery.
  • At this time T1-weighted imaging showed Gd-enhanced lesions with enlargement only of the cerebellar tumor.
  • Genetic analysis demonstrated positive FGFR 1 and less FGFR 2 mRNA in the tumor tissue, and FGFR 1 mRNA was beta type dominant.
  • These results indicated that the genetic features of this tumor are similar to those of glioblastoma multiforme concerning FGFR expression.
  • The authors conclude that genetic investigation of the tumor tissue is required to predict the prognosis of gliomatosis cerebri patients, in addition to imaging and histological examinations.
  • [MeSH-minor] Adult. Antigens, Nuclear. Biomarkers, Tumor / genetics. Cerebellar Neoplasms / chemistry. Cerebellar Neoplasms / diagnosis. Cerebellar Neoplasms / genetics. Cerebellar Neoplasms / pathology. Cerebellar Neoplasms / surgery. Combined Modality Therapy. Contrast Media. Fatal Outcome. Gadolinium DTPA. Humans. Magnetic Resonance Imaging. Male. Neoplasm Proteins / genetics. Nuclear Proteins / analysis. RNA, Messenger / analysis. RNA, Neoplasm / analysis. Receptor Protein-Tyrosine Kinases / genetics. Receptor, Fibroblast Growth Factor, Type 1. Receptor, Fibroblast Growth Factor, Type 2. Receptors, Fibroblast Growth Factor / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroradiology. 1999 Sep;41(9):650-3 [10525765.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(8):755-62 [9810441.001]
  • [Cites] Scott Med J. 1998 Jun;43(3):84-6 [9682295.001]
  • [Cites] Cancer. 1996 Oct 15;78(8):1789-93 [8859193.001]
  • [Cites] AJR Am J Roentgenol. 1993 Oct;161(4):859-62 [8372774.001]
  • [Cites] Clin Neuropathol. 1985 Jul-Aug;4(4):135-48 [4053456.001]
  • [Cites] Neuroradiology. 1996 Jul;38(5):444-8 [8837088.001]
  • [Cites] Radiology. 1996 Mar;198(3):831-5 [8628879.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):484-8 [8290551.001]
  • [Cites] Pediatr Neurol. 1999 Feb;20(2):148-51 [10082346.001]
  • [Cites] Acta Radiol. 1997 May;38(3):381-90 [9191428.001]
  • [Cites] Surg Neurol. 1991 Dec;36(6):431-40 [1759182.001]
  • [Cites] Brain Tumor Pathol. 1998;15(2):111-6 [10328549.001]
  • [Cites] Eur J Radiol. 1998 Oct;28(3):226-9 [9881257.001]
  • [Cites] Glia. 1999 Oct;28(1):66-76 [10498824.001]
  • [Cites] No To Shinkei. 1996 Apr;48(4):363-70 [8679334.001]
  • (PMID = 11519853.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / Biomarkers, Tumor; 0 / Contrast Media; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptors, Fibroblast Growth Factor; EC 2.7.10.1 / FGFR1 protein, human; EC 2.7.10.1 / FGFR2 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 1; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 2; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


28. Gumprecht H, Grosu AL, Souvatsoglou M, Dzewas B, Weber WA, Lumenta CB: 11C-Methionine positron emission tomography for preoperative evaluation of suggestive low-grade gliomas. Zentralbl Neurochir; 2007 Feb;68(1):19-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 11C-Methionine positron emission tomography for preoperative evaluation of suggestive low-grade gliomas.
  • OBJECTIVE: The treatment regimen for cerebral gliomas is different, depending on the histological grade of the lesion.
  • The therapeutic strategy for anaplastic gliomas and glioblastomas is more aggressive, including microsurgical removal, radiation and chemotherapy.
  • The management for low-grade gliomas is still under discussion, operation or "wait and see" tactics are possible options.
  • Therefore the diagnostic imaging procedures are crucial for further treatment planning.
  • Although most of the low-grade gliomas appear as hypointense lesions without contrast medium (CM) enhancement on magnetic resonance images, in some cases lesions without CM enhancement can be anaplastic tumours as well.
  • 11C-Methionine positron emission tomography (MET-PET) was performed for preoperative evaluation of non or low CM enhancing intracerebral lesions, so-called suggestive low-grade gliomas.
  • METHOD: 20 patients harbouring suggestive low-grade gliomas were included.
  • Histologically the 2 patients with sparse CM enhancement and MET uptake were glioblastoma multiforme, 10/14 patients with MET uptake and without CM enhancement had an anaplastic astrocytoma WHO III, 3/14 with MET uptake and no CM enhancement had an anaplastic oligoastrocytoma WHO III, and 1/14 had an oligoastrocytoma grade II.
  • The lesions of the 4 patients without MET uptake and without CM enhancement were classified as astrocytoma grade II in 2 cases, as astrocytoma grade I in 1 case and as astrocytoma III in one case.
  • CONCLUSION: According to the results of this study, we find MET-PET to be a helpful tool for pretreatment evaluation of non-CM enhancing, suggestive low-grade intracerebral lesions.
  • MET-PET adds valuable information for the decision-making for surgery or stereotactic biopsy.
  • [MeSH-minor] Astrocytoma / radionuclide imaging. Astrocytoma / surgery. Glioblastoma / radionuclide imaging. Glioblastoma / surgery. Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Neurosurgical Procedures. Positron-Emission Tomography

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17487804.001).
  • [ISSN] 0044-4251
  • [Journal-full-title] Zentralblatt für Neurochirurgie
  • [ISO-abbreviation] Zentralbl. Neurochir.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; AE28F7PNPL / Methionine
  •  go-up   go-down


29. Di Maio S, Gul SM, Cochrane DD, Hendson G, Sargent MA, Steinbok P: Clinical, radiologic and pathologic features and outcome following surgery for cervicomedullary gliomas in children. Childs Nerv Syst; 2009 Nov;25(11):1401-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of 78 brainstem tumors, nine cervicomedullary tumors undergoing resection were identified: two pilocytic astrocytomas, two gangliogliomas, and five grade II astrocytomas.
  • Initial treatment was surgery in seven: biopsy (1), <25% resection (4), and 25-50% resections (2).
  • Bulbar worsening occurred in five of six patients with interposed areas of non-enhancement versus one of three patients without interposed non-enhancing tissue (P = 0.014).
  • Additionally, bulbar worsening occurred in five of five patients with a poorly defined tumor/brainstem interface and abnormal low T1 signal extending beyond obvious tumor into the brainstem versus one of four with a well-defined tumor margin (P = 0.008).
  • Following chemo- or radiotherapy, the definition of the brainstem/tumor interface improved.
  • CONCLUSION: A less aggressive initial surgical approach, supplemented by postoperative chemotherapy, designed to preserve brainstem function, is proposed for patients with interposed non-enhancing tissue continuous with normal cervical cord or medulla and/or a poorly defined ventral tumor/brainstem interface with abnormal low T1 signal extending beyond obvious tumor into the brainstem.
  • [MeSH-minor] Cervical Vertebrae. Chemotherapy, Adjuvant. Child. Child, Preschool. Cohort Studies. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Medulla Oblongata / pathology. Medulla Oblongata / surgery. Neurons / pathology. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2006 Apr;27(4):786-93 [16611765.001]
  • [Cites] Acta Neurochir (Wien). 2007 Nov;149(11):1117-31; discussion 1131 [17712509.001]
  • [Cites] J Neurosurg. 1987 Oct;67(4):483-7 [3309202.001]
  • [Cites] Pediatr Neurosurg. 1997 Sep;27(3):153-9 [9548526.001]
  • [Cites] J Neurosurg. 2005 Dec;103(6 Suppl):557-62 [16383256.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1266-72 [16525181.001]
  • [Cites] Surg Neurol. 2007 Feb;67(2):156-9; discussion 159 [17254873.001]
  • [Cites] J Neurosurg Pediatr. 2008 Apr;1(4):270-6 [18377301.001]
  • [Cites] Childs Nerv Syst. 1999 Nov;15(11-12):758-63 [10603019.001]
  • [Cites] J Neurosurg. 1993 Mar;78(3):408-12 [8433142.001]
  • [Cites] Surg Neurol. 2007 Sep;68(3):285-91; discussion 291 [17719968.001]
  • [Cites] Am J Dis Child. 1970 Jun;119(6):465-72 [4315314.001]
  • [Cites] J Neurooncol. 1996 May-Jun;28(2-3):193-205 [8832462.001]
  • [Cites] Pediatr Neurosurg. 1991-1992;17(5):239-44 [1822689.001]
  • [Cites] J Neurosurg. 1986 Jan;64(1):11-5 [3941334.001]
  • [Cites] Neurosurgery. 1987 Mar;20(3):439-44 [3574621.001]
  • (PMID = 19636567.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


30. Suárez JC, Viano JC, Zunino S, Herrera EJ, Gomez J, Tramunt B, Marengo I, Hiramatzu E, Miras M, Pena M, Sonzini Astudillo B: Management of child optic pathway gliomas: new therapeutical option. Childs Nerv Syst; 2006 Jul;22(7):679-84

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To present our experience in the treatment of child optic pathway gliomas in the last 25 years.
  • One of the patients presented neurofibromatosis type 1 (NF1), another patient had Down syndrome.
  • Diagnosed using computed tomography or/and magnetic resonance imaging, histological studies showed pilocytic astrocytomas in 13 cases and a fibrillary astrocytoma grade II in 1 case.
  • The treatment consisted of surgery, external beam radiotherapy, chemotherapy, and brachytherapy with iodine 125, separately or combined.
  • Five patients died; the causes were secondary tumors in two children, tumor recurrence in one, sepsis secondary to respiratory and urinary tract infections in the child with Down syndrome, and finally, hydrocephaly due to hyperproteinorachia of tumor origin in one.
  • CONCLUSION: Chemotherapy and brachytherapy are therapeutic methods to be considered, especially in children under 5.
  • Marsupialization of the residual cyst into the ventricular system postradio or oncolytic treatment through endoscopic or stereotactic techniques is useful in the treatment of endocranial hypertension and/or hypothalamic compression in these patients.
  • [MeSH-major] Glioma / therapy. Optic Nerve Glioma / therapy. Optic Nerve Neoplasms / therapy
  • [MeSH-minor] Child. Child, Preschool. Female. Humans. Infant. Magnetic Resonance Imaging / methods. Male. Neurosurgery. Radiotherapy. Tomography, X-Ray Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Neurosurg. 1993 Jul-Aug;19(4):186-95 [8329303.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):215-25 [8420869.001]
  • [Cites] Ann Neurol. 1988 Jan;23 (1):79-85 [3345069.001]
  • [Cites] Childs Nerv Syst. 1999 May;15(5):256-60; discussion 261 [10392498.001]
  • [Cites] Cancer. 1987 Mar 1;59(5):1000-4 [2434201.001]
  • [Cites] Neurochirurgie. 1981;27(5):295-8 [7038523.001]
  • [Cites] Can J Neurol Sci. 2002 May;29(2):132-8 [12035834.001]
  • [Cites] Acta Neurochir (Wien). 1992;119(1-4):53-61 [1481753.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):807-12 [12788189.001]
  • [Cites] J Neurosurg. 1991 May;74(5):701-8 [1901597.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Dec;23(9):572-7 [11902299.001]
  • [Cites] Childs Nerv Syst. 2003 Mar;19(3):145-51 [12644865.001]
  • (PMID = 16389565.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


31. Aryan HE, Meltzer HS, Lu DC, Ozgur BM, Levy ML, Bruce DA: Management of pilocytic astrocytoma with diffuse leptomeningeal spread: two cases and review of the literature. Childs Nerv Syst; 2005 Jun;21(6):477-81
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of pilocytic astrocytoma with diffuse leptomeningeal spread: two cases and review of the literature.
  • INTRODUCTION: Leptomeningeal dissemination of juvenile pilocytic astrocytoma (JPA) is a rare event.
  • We report two children with disseminated JPAs treated with a chemotherapeutic agent, temozolomide, after progression of the disease despite surgery, traditional chemotherapy, and/or radiation therapy.
  • Ventriculoperitoneal shunting, decompressive laminectomy with spinal tumor debulking, and chemotherapy with carboplatin and vincristine were initially employed.
  • Biopsy was performed followed by chemotherapy with vincristine, cyclohexylchloroethylnitrosourea (CCNU), 6-TG, and procarbazine.
  • DISCUSSION: We review the literature and discuss treatment strategies for this challenging disease.
  • [MeSH-major] Arachnoid Cysts / therapy. Astrocytoma / therapy. Brain Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents, Alkylating / therapeutic use. Child. Child, Preschool. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Female. Humans. Magnetic Resonance Imaging / methods. Neurosurgery. Radiotherapy. Treatment Outcome

  • Genetic Alliance. consumer health - Diffuse Astrocytoma.
  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Childs Nerv Syst. 1997 Jan;13(1):17-23 [9083697.001]
  • [Cites] J Neurosurg. 1994 Jul;81(1):24-30 [8207524.001]
  • [Cites] Ann Oncol. 2001 Feb;12 (2):259-66 [11300335.001]
  • [Cites] Neurosurg Rev. 1996;19(4):217-20 [9007882.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2671-3 [8194003.001]
  • [Cites] Childs Brain. 1976;2(3):177-86 [971637.001]
  • [Cites] Neurology. 1976 Apr;26(4):322-5 [944389.001]
  • [Cites] Clin Neuropathol. 1988 Sep-Oct;7(5):254-8 [3208464.001]
  • [Cites] J Neurosurg. 1978 Jan;48(1):34-41 [412924.001]
  • [Cites] Neurology. 1988 Apr;38(4):562-6 [3352911.001]
  • [Cites] Cancer. 1993 May 15;71(10 ):3165-72 [8490847.001]
  • [Cites] Neurosurgery. 1994 Jan;34(1):68-78 [8121571.001]
  • [Cites] J Clin Oncol. 1993 May;11(5):850-6 [8487049.001]
  • [Cites] Cancer. 1987 Mar 1;59(5):1000-4 [2434201.001]
  • [Cites] J Neurooncol. 1996 Oct;30(1):47-54 [8865002.001]
  • [Cites] J Neurosurg. 1981 Jan;54(1):128-32 [7463115.001]
  • [Cites] Br J Neurosurg. 1998 Feb;12(1):56-8 [11013652.001]
  • [Cites] J Neurooncol. 2001 Jul;53(3):259-65 [11718258.001]
  • [Cites] Clin Neurol Neurosurg. 1995 Nov;97(4):300-6 [8599896.001]
  • [Cites] J Neurooncol. 2002 May;57(3):247-51 [12125988.001]
  • [Cites] Childs Brain. 1983;10(6):393-403 [6661937.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1375-82 [11870182.001]
  • [Cites] Surg Neurol. 1997 Jul;48(1):49-51; discussion 51-2 [9199684.001]
  • [Cites] Childs Nerv Syst. 1993 Sep;9(6):334-8 [8269416.001]
  • [Cites] J Neurosurg. 1991 Dec;75(6):972-5 [1941128.001]
  • [Cites] Childs Nerv Syst. 1998 Nov;14(11):617-22 [9840361.001]
  • [Cites] J Neurooncol. 2001 Jun;53(2):115-27 [11716065.001]
  • [Cites] J Neurosurg. 1992 Nov;77(5):788-91 [1403124.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2869-78 [8194029.001]
  • [Cites] Eur J Cancer. 2000 Sep;36(14 ):1788-95 [10974627.001]
  • [Cites] J Neurosurg. 1993 Aug;79(2):223-7 [8331404.001]
  • (PMID = 15378329.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  • [Number-of-references] 34
  •  go-up   go-down


32. Herrlinger U, Felsberg J, Küker W, Bornemann A, Plasswilm L, Knobbe CB, Strik H, Wick W, Meyermann R, Dichgans J, Bamberg M, Reifenberger G, Weller M: Gliomatosis cerebri: molecular pathology and clinical course. Ann Neurol; 2002 Oct;52(4):390-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomatosis cerebri is a rare, diffusely growing neuroepithelial tumor characterized by extensive brain infiltration involving more than two cerebral lobes.
  • Among 13 patients with gliomatosis cerebri (median age, 46 years), biopsies showed features of diffuse astrocytoma (n = 4), oligoastrocytoma (n = 1), anaplastic astrocytoma (n = 5), anaplastic oligoastrocytoma (n = 1), or glioblastoma (n = 2).
  • Molecular genetic investigation showed TP53 mutations in three of seven tumors and both PTEN mutation and epidermal growth factor receptor overexpression in one tumor.
  • Four of six patients treated with procarbazine, carmustine, vincristine chemotherapy demonstrated partial remission (one patient), minor response (two patients), or stable disease (one patient).
  • Median survival time from diagnosis was 14 months (range, 4-91+ months).
  • We conclude that (1) the molecular genetic alterations in gliomatosis cerebri resemble those in diffuse astrocytomas;.
  • (2) the prognosis of gliomatosis cerebri is variable but for at least 50% of patients as poor as for glioblastoma; and (3) some patients respond to radiotherapy and/or procarbazine, carmustine, vincristine chemotherapy.
  • [MeSH-minor] Adult. Aged. Cause of Death. Combined Modality Therapy. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Female. Genetic Markers. Humans. Male. Middle Aged. PTEN Phosphohydrolase. Phosphoric Monoester Hydrolases / genetics. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins c-mdm2. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12325066.001).
  • [ISSN] 0364-5134
  • [Journal-full-title] Annals of neurology
  • [ISO-abbreviation] Ann. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Genetic Markers; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; EC 3.1.3.- / Phosphoric Monoester Hydrolases; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


33. Broniscer A, Chintagumpala M, Fouladi M, Krasin MJ, Kocak M, Bowers DC, Iacono LC, Merchant TE, Stewart CF, Houghton PJ, Kun LE, Ledet D, Gajjar A: Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neurooncol; 2006 Feb;76(3):313-9
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
  • Chemotherapy is commonly used in the treatment of children with high-grade glioma, although its usefulness is uncertain.
  • We conducted a multi-institutional study to evaluate the efficacy of temozolomide given after radiotherapy in children with newly diagnosed high-grade glioma and unfavorable low-grade glioma (gliomatosis cerebri or bithalamic involvement).
  • Optional window therapy of intravenous irinotecan (10 doses of 20 mg/m2 per cycle x 2) was given over 6 weeks.
  • The predominant histologic diagnoses were glioblastoma multiforme (n = 15, 48%) and anaplastic astrocytoma (n = 10, 32%).
  • Two patients had bithalamic grade II astrocytoma.
  • Twenty-seven patients received radiotherapy (median dose: 59.4 Gy), including craniospinal irradiation in 3 because of leptomeningeal spread.
  • Four patients did not receive radiotherapy in this study because of consent withdrawn (n = 2), toxicity during window therapy (n = 1), or at the physician's discretion (n = 1).
  • Twenty-three patients received 112 cycles of temozolomide therapy.
  • Although the heterogeneity of prognostic factors in our patients made assessment of treatment outcome more difficult, the addition of 6 cycles of temozolomide after radiotherapy did not seem to alter the poor outcome of these patients.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Glioma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents, Phytogenic / therapeutic use. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1976 Dec;34(6):585-612 [795448.001]
  • [Cites] Ann Oncol. 2001 Feb;12 (2):259-66 [11300335.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12 ):3851-7 [9850030.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):261-7 [12356356.001]
  • [Cites] Br J Cancer. 2004 Aug 2;91(3):425-9 [15266331.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4684-91 [12488414.001]
  • [Cites] Br J Cancer. 1998 Sep;78(5):652-61 [9744506.001]
  • [Cites] J Neurooncol. 1989 Jul;7(2):165-77 [2550594.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2762-71 [10561351.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Dec;52(6):435-41 [13680158.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):112-23 [7799011.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3037-43 [9738573.001]
  • [Cites] Neuro Oncol. 2003 Jul;5(3):197-207 [12816726.001]
  • [Cites] Cancer. 2004 Aug 15;101(4):817-24 [15305415.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):264-71 [11815986.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] Cancer. 2005 Jan 1;103(1):133-9 [15565574.001]
  • [Cites] Clin Neuropathol. 2001 Nov-Dec;20(6):248-55 [11758780.001]
  • [Cites] Neurosurgery. 1996 Feb;38(2):258-64 [8869052.001]
  • [Cites] Cancer. 2000 Nov 15;89(10):2131-7 [11066055.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] Neuro Oncol. 2005 Jan;7(1):41-8 [15701281.001]
  • (PMID = 16200343.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA21765
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 0H43101T0J / irinotecan; 7GR28W0FJI / Dacarbazine; XT3Z54Z28A / Camptothecin; YF1K15M17Y / temozolomide
  •  go-up   go-down


34. Liang QC, Xiong H, Zhao ZW, Jia D, Li WX, Qin HZ, Deng JP, Gao L, Zhang H, Gao GD: Inhibition of transcription factor STAT5b suppresses proliferation, induces G1 cell cycle arrest and reduces tumor cell invasion in human glioblastoma multiforme cells. Cancer Lett; 2009 Jan 8;273(1):164-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of transcription factor STAT5b suppresses proliferation, induces G1 cell cycle arrest and reduces tumor cell invasion in human glioblastoma multiforme cells.
  • Moreover, immunohistochemical staining reveals that cytoplasm staining of STAT5b is markedly increased in GBM (57.1%) compared with that in normal cortex (22.2%) and diffuse astrocytoma (27.3%), suggesting that STAT5b could have important implications in astrocytoma biology.
  • Therefore, our findings illustrate the biological significance of STAT5b in GBM progression, and provide novel evidence that STAT5b may serve as a therapeutic target in the prevention of human glioblastoma multiforme.
  • [MeSH-major] Drug Delivery Systems. G1 Phase / drug effects. Gene Expression Regulation, Neoplastic. Glioblastoma / drug therapy. RNA, Small Interfering / pharmacology. STAT5 Transcription Factor / antagonists & inhibitors
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation / drug effects. Cell Survival. Humans. Immunohistochemistry. Protein Isoforms / antagonists & inhibitors. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Glioblastoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18793823.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / RNA, Small Interfering; 0 / STAT5 Transcription Factor; 0 / STAT5B protein, human
  •  go-up   go-down






Advertisement